Laura Guio Carrion

Laura Guio Carrion

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2014 in Clinical Microbiology and Infection
Verified
Journal Article
Open access
PDF file
Dolors Rodriguez-PardoDolors Rodriguez-Pardo
Dolors Rodriguez-Pardo
CPC. Pigrau
C. Pigrau
JLJ. Lora-Tamayo
J. Lora-Tamayo
ASAlex Soriano
Alex Soriano
MLMaría Dolores del Toro López
María Dolores del Toro López
JAJ. Ariza
J. Ariza
Prosthetic joint infection (PJI) is an uncommon complication (1–2%) of joint replacement surgery associated with high morbidity and medical expenditure [ 1 x 1 Huo, MH, Gilbert, NF, and Parvizi, J. What's new in total hip arthroplasty. J Bone Joint Surg Am. 2007; 89: 1874–1885 Crossref | PubMed | Scopus (22) | Google Scholar See all References , 2 x 2 Zimmerli, W, Trampuz, A, and Ochsner, PE. Prosthetic‐joint infections. N Engl J Med. 2004; 351: 1645–1654 Crossref | PubMed | Scopus (627) | Google Scholar See all References ]. The most frequently isolated microorganisms are gram-positive cocci. However, gram-negative bacteria (GNB) constitute 10–23% of all episodes, and these infections are often acute [ 3 x 3 Hsieh, PH, Lee, MS, Hsu, KY, Chang, YH, Shih, HN, and Ueng, SW. Gram‐negative prosthetic joint infections: risk factors and outcome of treatment. Clin Infect Dis. 2009; 49: 1036–1043 Crossref | PubMed | Scopus (92) | Google Scholar See all References , 4 x 4 Tattevin, P, Cremieux, AC, Pottier, P, Huten, D, and Carbon, C. Prosthetic joint infection: when can prosthesis salvage be considered?. Clin Infect Dis. 1999; 29: 292–295 Crossref | PubMed | Scopus (172) | Google Scholar See all References , 5 x 5 Zimmerli, W and Ochsner, PE. Management of infection associated with prosthetic joints. Infection. 2003; 31: 99–108 Crossref | PubMed | Scopus (237) | Google Scholar See all References ].

Verified
Journal Article
Open access
PDF file
Natividad BenitoNatividad Benito
Natividad Benito
IMIsabel Mur
Isabel Mur
ARAlba Ribera
Alba Ribera
ASAlex Soriano
Alex Soriano
Dolors Rodriguez-PardoDolors Rodriguez-Pardo
Dolors Rodriguez-Pardo
OMon behalf of the REIPI (Spanish Network for Research in Infectious Disease) Group for the Study of Prosthetic Joint Infections/GEIO (Group for the Study of Osteoarticular Infections), SEIMC (Spanish Society of Infectious Diseases and Clinical Microbiolo
on behalf of the REIPI (Spanish Network for Research in Infectious Disease) Group for the Study of Prosthetic Joint Infections/GEIO (Group for the Study of Osteoarticular Infections), SEIMC (Spanish Society of Infectious Diseases and Clinical Microbiolo
The aim of our study was to characterize the etiology of prosthetic joint infections (PJIs)—including multidrug-resistant organisms (MDRO)—by category of infection. A multicenter study of 2544 patients with PJIs was performed. We analyzed the causative microorganisms according to the Tsukayama’s scheme (early postoperative, late chronic, and acute hematogenous infections (EPI, LCI, AHI) and “positive intraoperative cultures” (PIC)). Non-hematogenous PJIs were also evaluated according to time since surgery: 12 months. AHIs were mostly caused by Staphylococcus aureus (39.2%) and streptococci (30.2%). EPIs were characterized by a preponderance of virulent microorganisms (S. aureus, Gram-negative bacilli (GNB), enterococci), MDROs (24%) and polymicrobial infections (27.4%). Conversely, coagulase-negative staphylococci (CoNS) and Cutibacterium species were predominant in LCIs (54.5% and 6.1%, respectively) and PICs (57.1% and 15.1%). The percentage of MDROs isolated in EPIs was more than three times the percentage isolated in LCIs (7.8%) and more than twice the proportion found in AHI (10.9%). There was a significant decreasing linear trend over the four time intervals post-surgery for virulent microorganisms, MDROs, and polymicrobial infections, and a rising trend for CoNS, streptococci and Cutibacterium spp. The observed differences have important implications for the empirical antimicrobial treatment of PJIs.

1 October 2013 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
ARAida Rodríguez-Sainz
Aida Rodríguez-Sainz
IEInés Escalza-Cortina
Inés Escalza-Cortina
LCLaura Guio Carrion
Laura Guio Carrion
AMAlexandra Matute-Nieves
Alexandra Matute-Nieves
MGMarian Gómez-Beldarrain
Marian Gómez-Beldarrain
JGJuan Carlos Garcia-Monco
Juan Carlos Garcia-Monco

21 April 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
HVHelem Vilchez
Helem Vilchez
Rosa Escudero-SanchezRosa Escudero-Sanchez
Rosa Escudero-Sanchez
MFMarta Fernandez-Sampedro
Marta Fernandez-Sampedro
Óscar MurilloÓscar Murillo
Óscar Murillo
ÁAÁlvaro Auñón
Álvaro Auñón
T(the Spanish Network for Research in Infectious Pathology (REIPI)
the Spanish Network for Research in Infectious Pathology (REIPI)
This retrospective, multicenter observational study aimed to describe the outcomes of surgical and medical treatment of C. acnes-related prosthetic joint infection (PJI) and the potential benefit of rifampin-based therapies. Patients with C. acnes-related PJI who were diagnosed and treated between January 2003 and December 2016 were included. We analyzed 44 patients with C. acnes-related PJI (median age, 67.5 years (IQR, 57.3–75.8)); 75% were men. The majority (61.4%) had late chronic infection according to the Tsukayama classification. All patients received surgical treatment, and most antibiotic regimens (43.2%) included β-lactam. Thirty-four patients (87.17%) were cured; five showed relapse. The final outcome (cure vs. relapse) showed a nonsignificant trend toward higher failure frequency among patients with previous prosthesis (OR: 6.89; 95% CI: 0.80–58.90) or prior surgery and infection (OR: 10.67; 95% IC: 1.08–105.28) in the same joint. Patients treated with clindamycin alone had a higher recurrence rate (40.0% vs. 8.8%). Rifampin treatment did not decrease recurrence in patients treated with β-lactams. Prior prosthesis, surgery, or infection in the same joint might be related to recurrence, and rifampin-based combinations do not seem to improve prognosis. Debridement and implant retention appear a safe option for surgical treatment of early PJI.

1 February 2009 in Revista Espanola de Cardiologia
Verified
Journal Article
Closed access
LCLaura Guio Carrion
Laura Guio Carrion
CSCristina Sarriá
Cristina Sarriá
CCCarmen de Las Cuevas
Carmen de Las Cuevas
CGCarlos Gamallo
Carlos Gamallo
JDJuan Duarte
Juan Duarte

23 July 2020 in medRxiv
Verified
Preprint
Open access
PDF file
GRGuillermo Ruiz-Irastorza
Guillermo Ruiz-Irastorza
JPJose-Ignacio Pijoan
Jose-Ignacio Pijoan
EBElena Bereciartua
Elena Bereciartua
SDSusanna Dunder
Susanna Dunder
JDJokin Dominguez
Jokin Dominguez
AMAgustin Martinez-Berriotxoa
Agustin Martinez-Berriotxoa
OBJECTIVE: To analyze the effects of a short course of methyl-prednisolone pulses (MP) during the second week of disease (week-2) in patients with severe coronavirus disease 2019 (COVID-19) pneumonia. METHODS: Comparative observational study using data collected from routine care at Hospital Universitario Cruces, Barakaldo, Bizkaia, Spain in patients with COVID-19 pneumonia. We compared patients who received week-2-MP (125250 mg/d x3) with those who did not, with the end-points time to death and time to death or endotracheal intubation. RESULTS: We included 242 patients with COVID-19 pneumonia and elevated inflammatory markers at admission. Sixty-one patients (25%) received week-2-MP. Twenty-two patients (9%) died and 31 (12.8%) suffered death or intubation. The adjusted HRs for death and death or intubation for patients in the week-2-MP group were 0.35 (95%CI 0.11 to 1.06, p= 0.064) and 0.33 (95%CI 0.13 to 0.84, p=0.020), respectively. These differences were specifically seen in the subcohort of patients with a SpO2/FiO2 at day 7 lower than 353 (adjusted HR 0.31, 95% CI 0.08 to 1.12, p=0.073 and HR 0.34, 95%CI 0.12 to 0.94, p=0.038, respectively) but not in patients with higher SpO2/FiO2. Patients receiving out-of-week-2-MP, non-pulse glucocorticoids or no glucocorticoids had an increased adjusted risk for both outcomes compared with week-2-MP group: HR 5.04 (95% CI 0.91-27.86), HR 10.09 (95% CI 2.14-47.50), HR 4.14 (95% CI 0.81-21.23), respectively, for death; HR 7.38 (95% CI 1.86-29.29), HR 13.71 (95% CI 3.76-50.07), HR 3.58 (95% CI 0.89-14.32), respectively, for death or intubation. These differences were significant only in the subgroup with low SpO2/FiO2. CONCLUSIONS: Week-2-MP are effective in improving the prognosis of patients with COVID-19 pneumonia with features of inflammatory activity and respiratory deterioration entering the second week of disease. The recognition of this high-risk population should prompt early use of MP at this point.